SCHEMBL285949

SCHEMBL285949

CC(N)C(=O)Oc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.53
ATM Q13315 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
SLC1A3 P43003 1/20 0.46
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP1A2 P05177 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ANPEP P15144 1/20 0.41
LAP3 P28838 1/20 0.41
MAPT P10636 2/20 0.41
TAAR1 Q96RJ0 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9939655 1.00 ELANE (0.53) ELANEATML3MBTL1SLC1A3ALDH1A1
SCHEMBL133568 1.00 ELANE (0.53) ELANEATML3MBTL1SLC1A3ALDH1A1
SCHEMBL28176721 0.98 ELANE (0.51) ELANEATML3MBTL1SLC1A3ALDH1A1
SCHEMBL28281300 0.98 ELANE (0.51) ELANEATML3MBTL1SLC1A3ALDH1A1
SCHEMBL28299146 0.98 ELANE (0.51) ELANEATML3MBTL1SLC1A3ALDH1A1
Hydrochloric Acid SCHEMBL10445713 0.98 ELANE (0.51) ELANEATML3MBTL1SLC1A3ALDH1A1
Ammonia Solution, Strong SCHEMBL9613925 0.98 ELANE (0.51) ELANEATML3MBTL1SLC1A3ALDH1A1
Ammonia Solution, Strong SCHEMBL2037585 0.98 ELANE (0.51) ELANEATML3MBTL1SLC1A3ALDH1A1
Hydrochloric Acid SCHEMBL19834657 0.98 ELANE (0.51) ELANEATML3MBTL1SLC1A3ALDH1A1
Malonic Acid SCHEMBL9222807 0.91 ELANE (0.46) ELANEATML3MBTL1SLC1A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119410679-A Method for optimizing antibody expression AMBRX公司 2025-02-11 CN claimed
CN-114380797-A Synthesis method of dabigatran etexilate 山东诚汇双达药业有限公司 2022-04-22 CN claimed
CN-110959041-A Methods and compositions for enhancing the production of proteins containing unnatural amino acids AMBRX公司 2020-04-03 CN claimed
CN-109844108-A Phosphorylation by regulating and controlling seryl-TRNA synzyme (SERRS) controls angiogenesis 斯克利普斯研究所 2019-06-04 CN claimed
US-9909135-B2 Transgenic plants having altered DAHP synthase activity YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2018-03-06 US claimed
CN-106188080-A A kind of D phenylalanine ring substituent norcantharidin derivative and preparation method and application 绍兴文理学院 2016-12-07 CN claimed
CN-106083873-A A kind of L phenylalanine ring substituent norcantharidin derivative and preparation method and application 绍兴文理学院 2016-11-09 CN claimed
WO-2016133917-A1 RAAV VECTOR COMPOSITIONS, METHODS FOR TARGETING VASCULAR ENDOTHELIAL CELLS AND USE IN TREATMENT OF TYPE I DIABETES UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2016-08-25 WO claimed
US-20150044734-A1 METABOLIC ENGINEERING OF THE SHIKIMATE PATHWAY THE REGENTS OF THE UNIVERSITY OF CALIFONIA (US) 2015-02-12 US claimed
EP-2702150-A1 LIPASE VARIANTS HAVING INCREASED ENZYME SPECIFICITY OR ENHANCED TRANS-SELECTIVITY, AND METHODS OF USE Frito-Lay Trading Company GmbH (CH) 2014-03-05 EP claimed
WO-2012146935-A1 LIPASE VARIANTS HAVING INCREASED ENZYME SPECIFICITY OR ENHANCED TRANS-SELECTIVITY, AND METHODS OF USE FRITO-LAY TRADING COMPANY, GMBH (CH) 2012-11-01 WO claimed
WO-2009029935-A1 DRUG DELIVERY VEHICLE THAT MIMICS VIRAL PROPERTIES UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2009-03-05 WO claimed
US-20080241895-A1 N-Acetyl-(R,S)-beta-Amino Acid Acylase Gene AJINOMOTO CO., INC. (JP) 2008-10-02 US claimed
US-5710296-A ESTERIFICATION, EXPOSURE OF ACTIVE INTERMEDIATE TO PHENOL TO FORM PHENYL ESTER THE CLOROX COMPANY (US) 1998-01-20 US claimed
EP-0109142-B1 PEPTIDE AND PSEUDOPEPTIDE DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-09-28 EP claimed
US-4474767-A Peptide and pseudopeptide derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-10-02 US claimed
EP-0109142-A2 Peptide and pseudopeptide derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1984-05-23 EP claimed
CN-115677718-B Methyl methylamine derivative preparation, pharmaceutical composition and application thereof 武汉思瓴生物科技有限公司 2024-11-01 CN disclosed
US-4371612-A Immobilization of biological material with an acrylonitrile polymer TOYO JOZO COMPANY, LTD. (JP) 1983-02-01 US disclosed
US-4336334-A FROM CULTURES OF METHYLOBACTERIUM IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1982-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080241895-A1 N-Acetyl-(R,S)-beta-Amino Acid Acylase Gene ACSL4, FASN, BLVRB ELANE 1330/4885ATM 2726/4885L3MBTL1 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.